Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor‐1 inhibitor TM5614 combined with a tyrosine kinase inhibitor

BACKGROUND: We recently showed that pharmacological inhibition of plasminogen activator inhibitor‐1 (PAI‐1) activity, based on TM5614, increases cell motility and induces the detachment of hematopoietic stem cells from their niches. In this TM5614 phase II clinical trial, we investigated whether the...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Naoto, Kameoka, Yoshihiro, Onizuka, Makoto, Onishi, Yasushi, Takahashi, Fumiaki, Dan, Takashi, Miyata, Toshio, Ando, Kiyoshi, Harigae, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972105/
https://www.ncbi.nlm.nih.gov/pubmed/36151699
http://dx.doi.org/10.1002/cam4.5292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972105/
https://www.ncbi.nlm.nih.gov/pubmed/36151699
http://dx.doi.org/10.1002/cam4.5292

Ejemplares similares